The FDA has approved a human clinical study of the EVO/EVO+ Visian ICL for myopia and the EVO/EVO+ Visian toric ICL for myopia with astigmatism, STAAR Surgical announced in a press release.
The study will include 300 subjects with a primary endpoint at 6 months’ follow-up, the release said.
“STAAR looks forward to the next step in moving our trial forward, gaining institutional review board approval and initiating the EVO/EVO+ clinical trial as soon as possible, which we anticipate will be during the first quarter of calendar 2020,” Caren Mason, (Read more...)
Uncategorized